Skip to main content
SpringerLink
Log in

Drug interactions are an important issue in type 2 diabetes

  • Drug Reactions and Interactions
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Patients with type 2 diabetes mellitus are often receiving multiple drugs to provide adequate glycaemic control and to treat co-morbidities, which are common in this population. The identification and management of clinically significant drug interactions, therefore, are important aspects of providing optimal care in patients with type 2 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311–21.

    Article  PubMed  Google Scholar 

  2. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–91.

    Article  CAS  PubMed  Google Scholar 

  3. Caughey GE, Roughead EE, Vitry AI, et al. Comorbidity in the elderly with diabetes: identification of areas of potential treatment conflicts. Diabetes Res Clin Pract. 2010;87(3):385–93.

    Article  PubMed  Google Scholar 

  4. Amin M, Suksomboon N. Pharmacotherapy of type 2 diabetes mellitus: an update on drug-drug interactions. Drug Saf. 2014;37(11):903–19.

    Article  CAS  PubMed  Google Scholar 

  5. Stage TB, Brosen K, Christensen MM. A comprehensive review of drug-drug interactions with metformin. Clin Pharmacokinet. 2015. doi:10.1007/s40262-015-0270-6.

    PubMed  Google Scholar 

  6. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2002;25(6):1033–41.

    Article  CAS  PubMed  Google Scholar 

  7. Kolaczynski JW, Ylikahri R, Harkonen M, et al. The acute effect of ethanol on counterregulatory response and recovery from insulin-induced hypoglycemia. J Clin Endocrinol Metab. 1988;67(2):384–8.

    Article  CAS  PubMed  Google Scholar 

  8. Hedenmalm K, Hagg S, Stahl M, et al. Glucose intolerance with atypical antipsychotics. Drug Saf. 2002;25(15):1107–16.

    Article  CAS  PubMed  Google Scholar 

  9. Korenyi C, Lowenstein B. Chlorpromazine induced diabetes. Dis Nerv Syst. 1968;29(12):827–8.

    CAS  PubMed  Google Scholar 

  10. Murphy MB, Lewis PJ, Kohner E, et al. Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up. Lancet. 1982;2(8311):1293–5.

    Article  CAS  PubMed  Google Scholar 

  11. Henriksen JE, Alford F, Ward GM, et al. Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Diabetologia. 1997;40(12):1439–48.

    Article  CAS  PubMed  Google Scholar 

  12. Miccoli R, Orlandi MC, Fruzzetti F, et al. Metabolic effects of three new low-dose pills: a six-month experience. Contraception. 1989;39(6):643–52.

    Article  CAS  PubMed  Google Scholar 

  13. Garg AGS. Nicotinic acid as therapy for dyslipidemia in noninsulin-dependent diabetes mellitus. JAMA. 1990;264(6):723–6.

    Article  CAS  PubMed  Google Scholar 

  14. Prokai A, Fekete A, Pasti K, et al. The importance of different immunosuppressive regimens in the development of posttransplant diabetes mellitus. Pediatr Diabetes. 2012;13(1):81–91.

    Article  CAS  PubMed  Google Scholar 

  15. Heisel O, Heisel R, Balshaw R, et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant. 2004;4(4):583–95.

    Article  PubMed  Google Scholar 

  16. Dachman AH. New contraindication to intravascular iodinated contrast material. Radiology. 1995;197(2):545.

    Article  CAS  PubMed  Google Scholar 

  17. McCartney MM, Gilbert FJ, Murchison LE, et al. Metformin and contrast media: a dangerous combination? Clin Radiol. 1999;54(1):29–33.

    Article  CAS  PubMed  Google Scholar 

  18. Krishnaiah YSR, Satyanarayana S, Visweswaram D. Interaction between tolbutamide and ketoconazole in healthy subjects. Br J Clin Pharmacol. 1994;37:205–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Niemi M, Backman JT, Neuvonen M, et al. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther. 2001;69(4):194–200.

    Article  CAS  PubMed  Google Scholar 

  20. Loupi E, Descotes J, Lery N, et al. Drug interactions involving miconazole. Therapie. 1982;37(4):437–41 (in French).

    CAS  PubMed  Google Scholar 

  21. Niemi M, Neuvonen PJ, Kivisto KT. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther. 2001;70(5):439–45.

    Article  CAS  PubMed  Google Scholar 

  22. Field JB, Ohta M, Boyle C, et al. Potentiation of acetohexamide hypoglycemia by phenylbutazone. N Engl J Med. 1967;277(17):889–94.

    Article  CAS  PubMed  Google Scholar 

  23. Christensen LK, Skovsted L. Inhibition of drug metabolism by chloramphenicol. Lancet. 1969;2(7635):1397–9.

    Article  CAS  PubMed  Google Scholar 

  24. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9(5):733–45.

    Article  CAS  PubMed  Google Scholar 

  25. Kendall DMRM, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083–91.

    Article  CAS  PubMed  Google Scholar 

  26. Zheng HX, Huang Y, Frassetto LA, et al. Elucidating rifampin’s inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther. 2009;85(1):78–85.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Zaman R, Kendall MJ, Biggs PI. The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide. Br J Clin Pharmacol. 1982;13(4):507–12.

    PubMed Central  CAS  PubMed  Google Scholar 

  28. Tracleer (bosentan) tablets: US prescribing information. South San Francisco: Actelion Pharmaceuticals US, Inc.; 2009.

  29. Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24(7):1226–32.

    Article  CAS  PubMed  Google Scholar 

  30. Avandia (rosiglitazone maleate) tablets: US prescribing information. Research Triangle Park: GlaxoSmithKline; 2014.

  31. Plosker GL. Dapagliflozin: a review of its use in patients with type 2 diabetes. Drugs. 2014;74(18):2191–209.

    Article  CAS  PubMed  Google Scholar 

  32. Patel CG, Li L, Girgis S, et al. Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. Clin Pharmacol. 2011;3:13–25.

    PubMed Central  CAS  PubMed  Google Scholar 

  33. Janssen Research & Development LLC. Canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with other anti-hyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus (Endocrinologic and Metabolic Drugs Advisory Committee briefing materials). Titusville: Janssen Pharmaceuticals, Inc.; 2012.

Download references

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Ethics declarations

    Disclosure

    This article was adapted from Drug Safety 2014;37(11):903–19 [4] by salaried employees of Adis/Springer, and was not supported by any external funding.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Adis Medical Writers. Drug interactions are an important issue in type 2 diabetes. Drugs Ther Perspect 31, 350–354 (2015). https://doi.org/10.1007/s40267-015-0230-0

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-015-0230-0

    Keywords

    Search

    Navigation